RXDX-106 inhibits TAM and c-MET phosphorylation in vitro. This inhibition of TAM and c-MET activation in vitro is accompanied by a decrease in downstream MAPK and PI3K signaling and cell viability. It completely inhibits cellular proliferation and viability at sub-nanomolar concentrations in TAM-expressing cells.

TP-0903 is a selective Axl kinase inhibitor with IC50 of 27 nM.

UNC2250 is an inhibitor of Mer with IC50 of 1.7 nM.

R428 is a potent and selective small-molecule inhibitor (IC50=14 nM), and blocks the activities of Axl.

LDC1267 is a selective inhibitor of TAM and inhibits Tyro3, Axl and Mer with IC50 of < 5 nM, 8 nM, 29 nM, respectively.

ONO-7475 is a potent and selective inhibitor of active novel Axl/Mer tyrosine kinase with IC50 values of 0.7nM and 1nM, respectively. It potently arrested growth and induced apoptosis in acute myeloid leukemia with internal tandem duplication mutation of FMS-like tyrosine kinase 3.

Cabozantinib S-malate is a VEGFR2 inhibitor with IC50 of 0.035 nM. It also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM-11.3 nM.

BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, being 40-fold selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.

Gilteritinib hemifumarate is an inhibitor of FLT3 and AXL with IC50 of 0.29 nM and 0.73 nM, respectively.

SC13 specifically inhibits FEN1 activity. It suppresses cancer cell proliferation and induces chromosome instability and cytotoxicity in cells, as well as sensitizes cancer cells to DNA damage-inducing therapeutic modalities and impedes cancer progression in a mouse model.

NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.

SGI-7079, a selective Axl inhibitor, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.

Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/< 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.